Liquid Biopsy Presentations and Case Studies

Liquid biopsy has been gaining traction within cancer research as a complementary or alternative technique to solid tissue biopsy due to a few factors:

  • Less invasive procedure enabling sampling at multiple time points to monitor progression of the cancer in research settings
  • Better representation of tumor heterogeneity
  • Faster turnaround time from sample to results
  • Lower costs compared with traditional tissue biopsies

Hear what your peers are doing in liquid biopsy through the testimonials, videos, case studies, and more below. 

Featured webinar series: New frontiers in liquid biopsy research
Bellosillo

Adding CNVs and fusions to a lung cfDNA assay: impact on oncology research

  • Dr. Beatriz Bellosillo, Head of Pathology at Hospital del Mar, discusses her experience evaluating the Oncomine Lung cfDNA Assay
  • Dr. Kelli Bramlett, Sr. Director of R&D for Clinical NGS at Thermo Fisher Scientific, presents a new white paper that showcases performance of the new variant types introduced in the evaluated assay

View webinar ›

Quagliata

Evaluation of a pan-cancer cell-free assay to meet unmet research needs

  • Dr. Luca Quagliata, Consultant for Molecular Pathology at the University of Basel, shares his lab's two specific unmet needs that lead to the evaluation, adoption, and implementation of the Oncomine Pan-Cancer Cell Free Assay

View webinar ›

Quagliata

From qualitative to quantitative: experiences with a cfDNA assay in metastatic breast cancer research

  • Dr. Liya Xu, Postdoctoral Scholar in the Kuhn/Hicks Laboratory at USC Michelson Center for Convergent Bioscience, discusses her team's work using liquid biopsy technology for breast cancer research
  • Data is shared that demonstrates integration of analytical variables of cfDNA samples obtained from the Oncomine Breast cfDNA assay v2 and genomic analysis and protein marker data from single circulating tumor cells


Testimonials

Detection of rare mutations like EGFR T790M down to 0.14% AF

webinar-mutation-analysis-cfdna-lung-tumor

“Using the Oncomine Lung cfDNA Assay, we were able to amplify more difficult samples.  The assay allowed us the detection of mutations like EGFR T790M down to 0.14% allelic fraction.”

—Dr. Jose Luis Costa, Senior Researcher, Institute of Molecular Pathology and Immunology of the University of Porto, Portugal

Detection of genomic heterogeneity in metastatic colorectal cancer samples

webinar-lung-cancer-liquid-biopsy-analysisa

“Genomic heterogeneity after anti-EGFR therapy was successfully detected in 94% of the research metastatic colorectal cancer samples using a next-generation sequencing multibiomarker approach. The Oncomine Colon cfDNA Assay enabled detection of somatic mutations with MAF >0.1%.”

—Dr. Bea Bellosillo, Head of Section, Hospital del Mar, Spain


Case studies

Variant detection in cell-free DNA from NSCLC using NGS

Dr. Stockley
  • Dr. Tracy Stockley presents the utilization of NGS and cell-free DNA for detection of EGFR T790M resistance mutation
  • Focuses on mutation detection in cell-free DNA and comparison with droplet digital PCR technology

An international multi-center study evaluates use of cfDNA for tracking tumor heterogeneity and evolution in lung cancer

webinar-lung-caner-cell-free-dna-study
  • Dr. Nicola Normanno presents the results of an international multi-center study
  • Focuses on tumor heterogeneity and evolution that could change treatment decisions in the future

Mutational analysis of cfDNA in a lung tumor

webinar-mutation-analysis-cfdna-lung-tumor
  • Dr. José Luis Costa presents data obtained running cfDNA from plasma samples on the Ion S5 System
  • Focuses on expected results from a research study monitoring a lung tumor